Antimicrobial Dose Selection under the Animal Rule

Area of Science:

• Regulatory Science
• Pharmacology
• Infectious Diseases

Background:

• The U.S. Food and Drug Administration (FDA) established the "Animal Rule" to facilitate the development of medical countermeasures against chemical, biological, radiological, or nuclear (CBRN) threats.
• This rule allows for the approval of drugs and biologics when human efficacy studies are not feasible or ethical, such as for conditions arising from exposure to CBRN agents.
• Determining the appropriate human dose is a critical challenge under this regulatory framework.

Purpose of the Study:

• To review the essential pharmacokinetic and pharmacodynamic data required for human dose selection of antimicrobials under the FDA's Animal Rule.
• To discuss methodologies for integrating diverse evidence, including in vitro, animal, and human data, to establish effective human doses.
• To illustrate the application of a totality of evidence approach through case studies.

Main Methods:

• Comprehensive review of regulatory guidance and scientific literature pertaining to the FDA's Animal Rule.
• Analysis of pharmacokinetic (PK) and pharmacodynamic (PD) principles relevant to dose determination.
• Examination of case studies demonstrating the integration of in vitro, animal, and human clinical pharmacology data.

Main Results:

• Identified key PK/PD parameters crucial for antimicrobial dose selection under the Animal Rule.
• Demonstrated that a "totality of evidence" approach, integrating data from multiple sources, is essential for robust dose justification.
• Case studies highlight the successful application of this integrated approach for various antimicrobial agents.

Conclusions:

• The Animal Rule necessitates a rigorous, integrated approach to human dose selection for antimicrobials.
• Pharmacokinetic and pharmacodynamic data, combined with a totality of evidence strategy, are vital for ensuring drug efficacy and safety under this pathway.
• This review provides a framework for regulatory agencies and drug developers navigating dose determination for CBRN threat countermeasures.